News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

MaxCyte, Inc. Introduces Rapid, Automated, Scalable Flow Electroporation-Based Technology For Vaccine Development


3/20/2014 10:11:22 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

GAITHERSBURG, Md.--(BUSINESS WIRE)--MaxCyte®, Inc., the pioneer in scalable, high-performance cell transfection systems, will present data in both a scientific talk and a poster during the World Vaccine Congress on March 24-26, 2014, that demonstrates the use of flow electroporation for the rapid and scalable transfection of cells in vaccine development. The data will show that MaxCyte’s technology enables the manufacture of multiple-gram quantities of recombinant protein antigens, virus-like particles (VLPs), viral vectors, or viruses for tens of thousands of doses in a single process run.

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com


comments powered by Disqus
   
Vaccine

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES